Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 2/20 | 0.30 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.30 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23621398 | 0.84 | KISS1R (0.38) | KISS1RMMP8ANPEPRNPEPDNPEP | |
| SCHEMBL14269798 | 0.83 | LMNA (0.35) | KISS1R | |
| SCHEMBL21424796 | 0.79 | KISS1R (0.39) | KISS1R | |
| SCHEMBL15583521 | 0.77 | LMNA (0.39) | — | |
| SCHEMBL26309095 | 0.75 | KISS1R (0.33) | KISS1R | |
| SCHEMBL20714652 | 0.75 | KDM4E (0.39) | MMP8 | |
| SCHEMBL21374424 | 0.75 | KDM4E (0.30) | — | |
| SCHEMBL20102811 | 0.75 | KDM4E (0.39) | MMP8 | |
| SCHEMBL23451084 | 0.75 | KDM4E (0.39) | MMP8 | |
| SCHEMBL20740687 | 0.74 | ANPEP (0.41) | KISS1RMMP8ANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | disclosed |
| US-20200283491-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283491-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | KISS1R 228/4885MMP8 2509/4885ANPEP 194/4885 |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | KISS1R 228/4885MMP8 2509/4885ANPEP 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.